1. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7: 1–94.
2. Nixon RM, Muller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009; 63 (5): 766–75.
3. Neutel J et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19: 447–58.
4. Sawada T et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks. KYOTO HEART Study Eur Heart J 2009; 30 (20): 2461–9.
5. Thürmann PA, Kenedi P, Schmidt A et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–42.
6. Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76–86.
7. Dahlof B, Devereux RB, Kristiansson K et al. LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study: a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
8. Schmidt and Schmieder. Hypertension and LVH: How much attention should we pay to the RAAS. Dialogues on Cardiovascular Medicine 2005; 10 (1): 36.
9. Robert H. Fagard, Hilde Celis, Lutgarde Thijs and Stijn Wouters. Regression of left ventricular mass by antihypertensive Tteatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084–91.
10. Wachtell K et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke cmpared to atenolol. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 2005; 45: 712–9.
11. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18 (5): 1540–6.
12. Burgess E, Bakris G, Weir M, Koval S. Comparative long term effects of two AT 1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. J Hypertens 2007; 25 (Suppl. 2): S27.
13. Haller H, Ito S, Izzo JL et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 9907.
14. Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008; 148: 30–48.
15. Xie QY, Wang YJ, Sun ZL, Yang TL. Effects of valsartan and indapamide on plasma cytokines in essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31 (5): 629–34.
16. Manabe S, Okura T, Watanabe S et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46 (6): 735–9.
17. Nakamura T, Fujii S, Hoshino J et al. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28 (12): 937–43.
18. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360: 1903–13.
19. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
20. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951–8.
21. Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
22. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008; 359 (12): 1225–37.
23. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100 (8): 1254–62.
24. Sipahi I, Debanne SM, Rowland DY et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627–36.
25. Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008; 26 (4): 622–9.
26. Chin HJ, Oh SW, Goo HS et al. and members of the PREMIER Group Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J Korean Med Sci 2011; 26 (1): 59–66.
27. FDA Drug Safety Communication: Ongoing safety review of the angiotensin receptor blockers and cancer 2010.
28. Bramlage P and Hasford J. Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany. Institutfür Medizinische Informations verarbeitung, Biometrie und Epidemiologie, University of Munich, Germany. Cardiovasc Diabetol 2009; 8: 18.
29. Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich) 2002; 4 (6): 424–32.
30. Fogari R, Corradi I, Poletti L et al. Sexual activity in hypertensive emales treated with valsartan or carvedilol. A cross-over study. J Hypertens 1999; 17 (Suppl. 3): S65.
Авторы
Ю.Н.Еремина, М.В.Леонова, А.А.Галицкий
Кафедра клинической фармакологии ГБОУ ВПО Российский национальный исследовательский университет
им. Н.И.Пирогова Минздрава РФ